Urinary tract infections (UTIs) are among the most common infectious diseases occurring in either the community or healthcare settings. A wide variety of bacteria are responsible for causing UTIs, however extra-intestinal pathogenic E. coli or ExPEC) remains the most common etiological agent. Since 2000, resistance to antibiotics emerged globally among ExPEC and is causing delays in appropriate therapy with subsequent increased morbidity and mortality. For patients with acute uncomplicated lower UTIs, nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin or pivmecillinam should be prescribed for a 1-5 day course depending on the agent used. Single-dose fosfomycin is an excellent option for uncomplicated lower UTIs and has had similar clinical and/or bacteriological efficacy for 3-or 7-day regimens for alternate agents (i.e., ciprofloxacin, norfloxacin, cotrimoxazole or nitrofurantoin). The aim of this review article is to provide an overview on the definitions, etiology, treatment guidelines (including agents for 1 infections due to antimicrobial resistant bacteria) of lower UTIs and to highlight recent aspects on antimicrobial resistance of ExPEC.
Introduction
Urinary tract infections (UTIs) are among the most common infectious diseases occurring in either the community or healthcare settings. In North America, these infections account for over 10 million physician visits annually, 1 million emergency department visits, and over 100,000 hospitalizations annually, with an estimated cost of $1 billion per year in the U.S [1] .
UTIs accounts for substantial morbidity, mortality and medical expenses on a global scale and it is estimated that approximately 20% of women over the age of 18 -29 years will suffer from an UTI during their lifetimes [2] . Moreover, UTIs are the most common bacterial infections found in nursing home residents, accounting for 50% of reported infections in Norwegian nursing homes, 30% to 50% in U.S. nursing homes, and 25% of all infections in the noninstitutionalized elderly in the U.S. Recurrent or relapsing UTIs are especially problematic in many individuals.
A wide variety of bacteria are responsible for causing UTIs, however Escherichia coli remains the most common etiological agent [1] . E. coli is an incredible versatile bacterium in that it has the ability to colonize numerous hosts (including humans) and forms an important part of the normal intestinal flora. Sometimes E. coli acquires pieces of DNA that gives it the ability to cause various diarrheal diseases and is referred to as an intestinal-pathogenic E. coli.
However, there is another type of E. coli that has the capacity to cause infections outside the gastrointestinal system. These types of E. coli are referred to as extra-intestinal pathogenic E. promoter or attenuator mutations, which resulted in the up-regulation and production of the natural occurring chromosomal AmpC ß-lactamases [22] . Occasionally, cephamycin-resistant E. coli can also produce plasmid-mediated or imported AmpC -lactamases [19] .
AmpC -lactamases at high levels, hydrolyse penicillins, most cephalosporins, cephamycins and monobactams, but not the fourth generation cephalosporins (e.g. cefepime) and carbapenems ( Table 1 ). Resistance to the fourth generation cephalosporins are caused by point mutations in AmpC β-lactamases and is called extended-spectrum cephalosporinases. AmpC enzymes are not inhibited by "classical" -lactamase inhibitors, such as clavulanic acid, sulbactam and tazobactam, although boronic acids and cloxacillin have shown to be good inhibitors [23] . The genes are typically encoded on large plasmids containing additional antibiotic resistance genes that are responsible for multi-resistant phenotype, leaving few therapeutic options [21] .
Just like ESBL-producing bacteria, E. coli with plasmid-mediated AmpC enzymes have mostly been responsible for nosocomial outbreaks on a worldwide basis during the late 1980's and 1990's, although the risk factors associated with infection are not as well defined as those associated with ESBL-producing bacteria [21] . In a study reported from Korea, patients infected by plasmid-mediated AmpC-producing organisms had similar clinical features and outcomes to those patients infected with TEM-or SHV-related ESBL producers [24] .
It seems that CMY-2 (active on CephaMYcins) is the most common imported AmpC lactamase reported in Enterobacteriaceae (especially E. coli and Salmonella spp.) from different areas of the world [19] . Hospital surveys from Asia, North America and Europe have shown that the DHA types of cephamycinases are mostly present in Klebsiella spp from Asia, CMY are [25] [26] [27] [28] [29] .
KPC -lactamases
The most clinical significant of the class A carbapenemase is the KPC-types (i.e.
Klebsiella pneumoniae Carbapenemase) [30] . KPC-1 (it was later shown to be identical to KPC-2) was reported in the late 1990's from a K. pneumoniae isolated in North Carolina, USA and to date, more than 18 different KPC variants have been described [31] , even though KPC-2 and -3 remain the most commonly identified variants. These enzymes provide resistance to the carbapenems, cephalosporins, cephamycins and monobactams and are weakly inhibited by "classical" -lactamase inhibitors such as clavulanic acid and tazobactam (Table 1) . KPC lactamases (especially KPC-2 and -3) have been described in several enterobacterial species, especially Klebsiella spp. and to a lesser extent in Enterobacter spp. [30] .
Several nosocomial outbreaks, most often due to K. pneumoniae, have been reported from North America (especially the USA), South America (Colombia, Argentina), Europe (Greece, Italy, Poland), Asia (China) and Middle East (Israel) [31] [32] [33] . KPC-producing bacteria are considered to be endemic in certain parts of the world, such as the North Eastern USA, Puerto Rico, Colombia, Greece, Italy, Israel and China and are important causes of nosocomially-acquired infections in some parts of these countries ( Table 1 ) [33] . K. pneumoniae ST258 with KPC-2 and KPC-3 had significantly contributed to the world-wide distribution of this resistance trait [33] .
The genes responsible for the production of KPC enzymes are located on transferable plasmids and are associated with the mobile element transposon Tn4401, explaining their spread among clinically relevant pathogens [34] (Table 1 ). Plasmids that encode for KPC enzymes often contain several genes that encode for resistance to other antimicrobial agents, such as the aminoglycosides, plasmid-mediated quinolone resistance, trimethoprim, sulfonamides and tetracyclines. This ensures that KPC-producing Enterobacteriaceae are often multiresistant to various groups of antibiotics [35] .
NDM -lactamases
A new type of metallo-β-lactamase (MBL), named NDM (i.e. New Delhi metallo-βlactamases), was described in 2009 in K. pneumoniae and E. coli recovered from a Swedish patient who was hospitalized in New Delhi, India [36] . NDMs have the ability to hydrolyse a wide variety of -lactams, including the penicillins, cephalosporins and carbapenems, but not the monobactams (i.e. aztreonam), and are inhibited by metal chelators such as EDTA. NDM-1 shares very little identity with other MBLs, the most similar being VIM-1/VIM-2 with only 32.4% amino acid identity. Since the first description of NDM-1, more than eight variants of this enzyme have been described, with the majority of them originating from Asia [11] .
The majority of NDM-1-producing bacteria are broadly resistant to various drug classes and also carry a diversity of other resistance mechanisms (e.g. to aminoglycosides and fluoroquinolones), which leaves limited treatment options [37] . These additional mechanisms include the following: plasmid-mediated AmpC β-lactamases (especially CMY types), ESBLs (especially CTX-M-15), different carbapenemases (e.g. OXA-48-, VIM-, KPC-types), 16S RNA methylases, plasmid-mediated quinolone resistance determinants to quinolones, macrolide modifying esterases, and rifampicin-modifying enzymes. Consequently, Enterobacteriaceae with NDMs remain only susceptible to colistin, fosfomycin and tigecycline [11] .
Kumarasamy and colleagues [38] , provide compelling evidence that NDM-producing Enterobacteriaceae (mostly K. pneumoniae and E. coli) are widespread in India and Pakistan.
They also found that many UK patients infected with NDM-producing bacteria had recently traveled to India to undergo several types of medical procedures. The patients presented with a variety of hospital-and community-associated infections with urinary tract infections (UTIs) being the most common clinical syndrome. Recent reports from the subcontinent (including India, Pakistan and Bangladesh) showed that the distribution of NDM β-lactamases among Enterobacteriaceae was widespread through these countries [39, 40] [43] . The prevalence of asymptomatic fecal carriage was estimated to have been between 5 to 15 % in these countries [11] .
Since 2010 Enterobacteriaceae with NDMs have been reported worldwide from patients with an epidemiological link to the Indian subcontinent [44] . The impact of intercontinental travel as a source of spread of NDM producers has been extensively reported and these enzymes are now one of the most common carbapenemases identified in countries such as Canada, the UK and France [11] . Recent findings suggest that the Balkan states, North Africa and the Middle East might act as secondary reservoirs for the spread of NDMs, which may or may not initially have reached these countries from the Indian subcontinent [11] (Table 1 ).
Enterobacteriaceae (especially K. pneumoniae and E. coli) with NDMs, have been recovered from many clinical settings, reflecting the disease spectra of these opportunistic bacteria, including hospital and community-onset urinary tract infections, septicaemia, pulmonary infections, peritonitis, device-associated infections and soft tissue infections [37, 39, 44] . The frequent identification of NDMs within E. coli is of special concern because this organism is the most common cause of community and hospital onset urinary tract infections and diarrhea [88] . NDM-1-positive bacteria have been recovered from the gut flora of travelers returning from the Indian subcontinent and were undergoing microbiological investigation for unrelated diarrheal symptoms [45] . There is also widespread environmental contamination by NDM-1-positive bacteria in New Delhi [46] .
OXA-48-like β-lactamases
The Ambler class D ß-lactamases is commonly referred to as OXAs (i.e. "oxacillinases") and comprises over 400 enzymes and some variants possess carbapenemase activity [93] . These enzymes (also referred to as carbapenem-hydrolysing class D ß-lactamases or CHDLs) do not efficiently hydrolyse the oxyimino-cephalosporins or the monobactams (the exception being OXA-163) [37] . The CHDLs possess weak carbapenemase activities that do not confer high level resistance to carbapenems if not associated to other factors such as permeability defects.
The majority of CHDLs variants have been identified in Acinetobacter spp., but OXA-48 and its derivatives (i.e. OXA-163, OXA-181, OXA-204, and OXA-232) are most often encountered in Enterobacteriaceae [47] .
OXA-48 was first identified in 2003 from K. pneumoniae isolated in Turkey [48] and since then, bacteria that produce these β-lactamases, have been important causes of nosocomial outbreaks in this country [49] . The first report of OXA-48-producing K. pneumoniae outside Turkey was in 2007 from Belgium [50] and bacteria that produce OXA-48 have rapidly spread to several Belgian hospitals [51] . Since then Enterobacteriaceae with OXA-48 have disseminated throughout Europe, and it seems that Turkey and North African countries (especially Morocco and Tunisia [37] ) are the main reservoir for these infections. Subsequently several nosocomial outbreaks of OXA-48-producing K. pneumoniae, E. coli, and Enterobacter cloacae have been reported in France, Germany, Switzerland, Spain, the Netherlands and UK [47] .
The spread of OXA-48 is mostly due to a mobile 62.5-kb plasmid that belongs to the Inc L/M replicon group, as well as the presence of Tn1999 [47] . Interestingly, the 62.5-kb plasmid does not carry additional resistance genes. This plasmid has the ability to efficiently transfer resistance to other enterobacterial species. OXA-48-like enzymes have mostly been identified in K. pneumoniae and E. coli to a lesser extent and are not inhibited by metal chelators such as EDTA or "classical" β-lactamases inhibitors such as clavulanic acid or tazobactam ( Table 1 ).
The production of ESBLs and/or permeability barriers in bacteria that co-produce OXA-48 will increase the level of resistance to the cephalosporins and carbapenems [37] .
Several point mutant variants of OXA-48, most often in K. pneumoniae, have recently been reported. These includeed OXA-163, OXA-181, OXA-204 and OXA-232 [11] . OXA-163 differ from the other OXA-48-like enzymes in that its carbapenemase activity is low combined with enhanced hydrolysis of the oxyimino-cephalosporins providing isolates with resistance phenotypes similar to those bacteria with ESBL. OXA-163 was originally identified from enterobacterial isolates (E. cloacae and K. pneumoniae) recovered in Argentina, and it seems that Enterobacteriaceae with these oxacillinases are common in this South American country [11] .
MCR-1: plasmid-mediated colistin resistance
MCR-1, the first transferable plasmid-mediated colistin resistance gene, was reported in ExPEC isolates from food animals, food and patients in China [52] . Since then, detection of MCR-1-positive strains has been reported in several Enterobacteriaceae worldwide. Of clinical concern is the presence of plasmids containing MCR-1in ExPEC with carbapenemases. Such 14 isolates have the potential to create pandrug resistant bacteria originating mostly from the community that will nearly be impossible to treat effectively.
Guidelines for treating lower urinary tract infections
Although acute cystitis is one of the most common infections in ambulatory women, studies show that prescribing practices vary widely despite the publication of treatment guidelines by expert groups [53] [54] [55] . The Infectious Diseases Society of America (IDSA) and the European Society for Microbiology and Infectious Diseases initially published clinical practice guidelines for the treatment of acute uncomplicated cystitis in the 1990s [56] . However, in the intervening period, treatment approaches have become more complicated because of the steady rise in antimicrobial resistance amongst uropathogens, particularly E. coli [57] [58] [59] [60] [61] , requiring the IDSA and the ESMID to update their conjoint guidelines in 2010 [62] . Although ampicillin was initially the recommended treatment of choice for uncomplicated lower UTI, this is no longer the case because of the very high prevalence of antimicrobial resistance to both amoxicillin and ampicillin worldwide [63] [64] [65] . However, other B-lactams including cefdinir, cefaclor, amoxicillin-clavulanate and cefpodoxime-proxetil in 3-7 day regimens continue to be recommended for treatment of uncomplicated cystitis when susceptibility is confirmed, and other agents cannot be used [62] . However, many of these drugs have not been well studied for the treatment of UTI, and should currently be considered alternative agents as they generally have inferior efficacy and more adverse effects on the host's normal flora (i.e., Clostridium difficile) [62, 66, 67] . The fluoroquinolones including ofloxacin, norfloxacin, ciprofloxacin and levofloxacin are also currently being considered alternative antimicrobials for acute cystitis [62] .
Although fluoroquinolones are highly efficacious in a 3-day regimen, there has been a dramatic increase in resistance to these agents in Gram-negative uropathogens in the past decade, particularly due to the global dissemination of the ESBL-producing E. coli ST131, and
Pseudomonas aeruginosa for which there are currently no other orally available treatment options [57, 61, [68] [69] [70] . Fluoroquinolones also have potentially serious side effects (i.e., polyneuropathothy) and an increased risk of ecological disruption of the host normal flora (i.e., C. difficile), and should therefore be reserved for more important treatments other than acute cystitis [71, 72] . Figure 1 and Table 1 outline the current expert recommendations for the optimal treatment for acute uncomplicated cystitis [62] . For women with acute uncomplicated cystitis who are able to take oral medication, nitrofurantoin (NTF), trimethoprim-sulfamethoxazole (SXT), fosfomycin (FOS) or pivmecillinam (PVM) should be prescribed for a 3-5 day course depending on the agent used. Nitrofurantoin monohydrate/macrocrystals is an appropriate treatment choice due to the minimal resistance [62] , efficacy and propensity to cause alteration in the host's flora compared to a 3-day course of SXT [73] . Although SXT is still widely used and recommended for acute cystitis therapy, the caveat is that local resistance rates of uropathogens should not exceed 20%, or if the infecting strain is confirmed to be susceptible [62] . The IDSA/ESMID chose a cut-off of 20% resistance rate for SXT based on clinical, in vitro and mathematical modelling studies with regards to the potential for treatment failure [62] .
Fosfomycin-trometamol can also be used if it is available because of minimal resistance and propensity for collateral damage [74, 75] . Although fosfomycin may be used for other indications, its use has been restricted to treatment of acute cystitis due to ESBL-producing E. coli or Klebsiella spp. Fosfomycin appears to have inferior efficacy however, when compared to other standard short course regimens according to data submitted to the US Food and Drug Administration (FDA) [76, 77] . Several other recent studies have demonstrated comparable *The choice between these agents should be individualized and based on patient allergy and compliance history, local practice patterns, local community resistance prevalence, availability, cost, and patient and provider threshold for failure (see Table 1) efficacy to other regimens [78] . Finally, Pivmecillinam is an appropriate choice for therapy in some European countries where it is available. This agent is currently not licensed and/or available in North America except through special authorization access. Use of this antimicrobial for acute uncomplicated UTI in Northern European countries for several decades has resulted in minimal resistance and propensity for collateral host damage [79, 80] . However, several recent studies have shown that Pivmecillinam may have inferior efficacy compared with other standard short course regimens, which could have been due to under dosing [81, 82] .
Women with an acute uncomplicated UTI who receive inadequate antimicrobial treatment may develop subclinical pyelonephritis with recurrent symptomatic infections with the same organism
[83].
Agents for treating lower urinary tract infections due to antimicrobial resistant bacteria
The emergence of multi-drug resistant Gram-negative bacilli has renewed interest in the use of older antimicrobial agents to treat uncomplicated UTIs, particularly those that have low levels of resistance against β-lactamase-producing Enterobacteriaceae. Although nitrofurantoin and SXT have been used worldwide for decades, fosfomycin, temocillin and pivmecillinam are not licensed and/or available in North America and many countries in Europe. As such, there is a paucity of international surveillance data because currently none of these drugs are part of an antibiotic resistant surveillance in developed countries. This section describes agents that have recently become part of the new IDSA treatment recommended for acute uncomplicated UTIs, specifically fosfomycin and pivmecillinam for ExPEC, when resistance to one or more of carbapenems, colistin, aminoglycosides and quinolones are present.
Fosfomycin
This compound has been in use for over forty years, and it has a unique mechanism of action. Fosfomycin-trometamol (FOS) is a phophonic acid derivative that acts as a bacterial cell wall inhibitor [84, 85] . The compound inhibits the UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), an enzyme responsible for ligating phosphoenolpyruvate to the 3'-hydroxyl group of UDP-N-acetylglucosamine in the first step of peptidoglycan synthesis [77, 84, 86] . The drug enters into the active site of MurA and inhibits the enzyme by covalent binding with the active site, Cys115 [87, 88] . Resistance most commonly occurs by decreased permeability, and enzymatic modification of FOS by plasmid-encoded glutathione transferases (encoded by mainly fosA, but also fosB, fosC, and fosX) [78, [87] [88] [89] . Uncommonly, the fosfomycin binding site Cys115 may also be changed via mutations in the genes encoding the hexose phosphate transport (UhpT) and glycerol-3-phosphate transport (GlpT) pathways [78, 87] . Resistance to FOS is rare considering the amount of time this compound has been used, due to the compound's unique structure and distinct mechanism of action [87, 88] . However, increasing reports of plasmidmediated FOS resistance signal that this trend may not last. The plasmid-mediate fosfomycin resistance gene fosA3 in E. coli was first described in Japan, and encodes a glutathione S- patients with various risk factors [74] . Cumulatively, treatment with FOS was associated with clinical cure in 75/80 (93.8%) patients [74] , but one of these studies reported a lower rate of microbiological clearance (41/52; 78.8%). However, in European countries where this antimicrobial has had widespread use for several decades, susceptibility levels have recently been shown to have substantially decreased, both in strains from ambulatory and hospitalized patients [70] .
More recent studies from both North America and Europe have focussed on the use of
FOS for lower urinary tract infections, particularly those due to ESBL-producing
Enterobacteriaceae since a single dose of FOS 3 g achieves a high concentration in urine [77, 114] , and is well tolerated, with only some nausea and diarrhoea being reported [77, 96] .
Keating [78] reviewed the results of clinical trials by focusing on the use of single-dose FOS treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Recent randomized trials showed that single-dose FOS had similar clinical and/or bacteriological efficacy to 3-or 7-day regimens for alternate agents (i.e., ciprofloxacin, norfloxacin, cotrimoxazole or nitrofurantoin) in women with uncomplicated UTIs.
A single-dose of FOS also had similar bacteriological efficacy to a 5-day course of cefuroxime axetil or a 7-day course of amoxicillin/clavulanic acid in pregnant women with asymptomatic bacturiuria, and similar clinical and/or bacteriological efficacy to a 5-day course of cefuroxime axetil or amoxicillin/clavulanic acid, or a 3-day course of ceftibuten in pregnant women with cystitis [78] .
FOS is also increasingly being used in hospitalized patients to primarily treat nosocomial UTIs, particularly for E. coli infection due to MDR strains, and in patients where other antimicrobials may be contraindicated due to collateral damage (i.e., C. difficile, patient allergies). A recent study also evaluated the use of FOS among inpatients at a tertiary care hospital in the United States between 2009 and 2013 [75] . The number of patients with UTIs that were treated with FOS substantially increased during this period, from none to 391 in 2013. Of the 537 patients who received FOS for any indication, physician-diagnosed UTI accounted for 74% of prescriptions, another 10% of treatments were due to asymptomatic bacturiuria, and the remainder had other indications including fever, leukocytosis, or sepsis of uncertain etiology [75] .
E. coli was the most common organism isolated from the 239 patients with UTI, and 20% of these isolates were MDR [75] . Almost all patients received a single-3g-dose of FOS, which resulted in an overall clinical success rate at 48 h of 74.8%. However, among the 89 patients with confirmed UTIs, according to national surveillance definitions, the success rate was much higher (89.9%). Recurrent infections occurred in only 4.3% of cases and the drug was welltolerated with only a few documented adverse events [75] .
A clinical trial is also underway in Spain investigating the clinical non-inferiority of intravenous FOS (4g/6h) compared to meropenem (1g/8h) for treating bacteremic urinary tract infections caused by ESBL-producing E. coli [115] . This phase III randomised controlled trial which completes enrollment in 2017, will compare the clinical and microbiological efficacy 5-7 days after treatment, and the safety of these two treatment arms. If FOS is shown to have noninferior results to the use of a carbapenem, the results may have justified the use of parenteral FOS as an alternate agent for treatment of selected patients with frequent complicated UTIs caused by MDR E. coli with susceptibility to this drug.
Pivmecillinam
This compound is the pro-drug of mecillinam (6β-amidinopenicillanic acid), which is a penicillin derivative that has been used extensively in Scandinavian countries since the 1980s for treatment of uncomplicated UTIs [116, 117] . Mecillinam disrupts cell wall synthesis by inhibiting penicillin-binding protein 2 (PBP2) [118, 119] , which is responsible for elongation of rod-shaped cells. The mechanism(s) of resistance to mecillinam are currently poorly understood although a recent study showed that mutation in cysB preventing the production cysteine was found in clinical isolates. The reduced cysteine levels led to an increased cellular concentration of the ppGpp molecule, which makes the drug's PBP2 target nonessential [120] .
Pivmecillinam (PVM) treatment causes minimal disruption to the gastrointestinal microbial flora, and the drug achieves high concentrations in urine [116, 117, 121] . PVM only has in vitro activity against Gram-negative organisms, but its extensive use for uncomplicated UTI has shown that it is safe during pregnancy, and effective for Staphylococcus saprophyticus infection because the high urine levels overcome in vitro resistance [79, 122] . Although the Swedish Reference Group for Antibiotics (www.srga.org) has published breakpoints for the susceptibility testing of PVM against uropathogens, a recent study suggested that these should be revised [122] . Monsen et al. [122] recently analyzed data from a prospective, multi-centre, placebo-controlled primary healthcare facility in Sweden of 1143 women with cystitis who were enrolled from 1995-98. The clinical and bacteriological outcomes of PVM treatment were evaluated in this cohort with a specific focus on patients with UTI due to a PVM resistant uropathogen. In vitro susceptibility to PVM did not predict clinical or bacteriological outcome of treatment irrespective of the type of uropathogen causing infection. 
Five Year View
ExPEC will continue to be the most common cause of uncomplicated UTIs on a worldwide basis. Resistance to different classes of antibiotics will continue to increase among global ExPEC due to the expansion of successful drug resistant clones such as E. coli ST131and
ST405. This will cause further delays in appropriate therapy of community and hospital onset UTIs with subsequent increased morbidity and mortality. The carbapenemases (e.g. NDMs, KPC and OXA-48), plasmid-mediated resistance to fosfomycin and colistin will most likely expand exponentially among ExPEC in the next few years or so.
The medical community urgently needs effective oral drugs for the treatment of uncomplicated UTIs. Unfortunately, the development of such new anti-infective agents will most likely not be available within the next 5 years.
Funding
This work was supported in part by a research grant from Calgary Laboratory Services (#10009392)
Key issues
 Urinary tract infections (UTIs) are among the most common infectious diseases occurring in either the community or healthcare settings.
 A wide variety of bacteria are responsible for causing UTIs, however Escherichia coli remains the most common etiological agent.
 Before the 2000's, ExPEC was susceptible to first line antibiotics (e.g. cephalosporins, cotrimoxazole, and fluroquinolones) that are often used to treat UTIs. Unfortunately since 2000, resistance to these antibiotics had emerged globally and is causing delays in appropriate therapy with subsequent increased morbidity and mortality.
 The most important β-lactamases in ExPEC are the extended-spectrum -lactamases
[ESBLs] (e.g. CTX-M types), plasmid-mediated or imported Amp C -lactamases (e.g. CMY types), and to a lesser extent the carbapenemases (e.g. KPC types, MBLs e.g. VIM, IPM and NDM types, and the oxacilinases e.g. OXA-48-like enzymes).
 For women with acute uncomplicated cystitis who are able to take oral medication, nitrofurantoin, trimethoprim-sulfamethoxazole (SXT), fosfomycin or pivmecillinam should be prescribed for a 1-5 day course depending on the agent used.
 Single-dose fosfomycin had similar clinical and/or bacteriological efficacy to 3-or 7-day regimens for alternate agents (i.e., ciprofloxacin, norfloxacin, cotrimoxazole or nitrofurantoin) in women with uncomplicated UTIs.
 Pivmecillinam is available in certain North European countries and is currently not licensed and/or available in North America. Several recent studies have shown that Pivmecillinam may have inferior efficacy when compared to other standard short course regimens.
